167,200 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Acquired by Castleark Management LLC

Castleark Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 167,200 shares of the company’s stock, valued at approximately $4,178,000. Castleark Management LLC owned approximately 0.23% of Kiniksa Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Quarry LP purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at $50,000. CWM LLC grew its stake in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. nVerses Capital LLC purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at about $80,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the second quarter valued at about $100,000. Finally, Lynx1 Capital Management LP purchased a new position in shares of Kiniksa Pharmaceuticals in the second quarter worth about $177,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on KNSA. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Trading Up 2.5 %

Shares of NASDAQ:KNSA opened at $21.51 on Friday. The company has a market capitalization of $1.55 billion, a PE ratio of -153.63 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The business has a 50 day moving average of $23.64 and a two-hundred day moving average of $23.01.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. The business’s revenue for the quarter was up 67.4% on a year-over-year basis. Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This represents a 28.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. The trade was a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,592 shares of company stock valued at $1,110,364 in the last ninety days. 54.57% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.